https://doi.org/10.55788/60147558
“Ineffectiveness, a delayed onset of action, and serious side effects are problems we encounter with conventional therapies for MG,” said Prof. Claeys. Fortunately, novel therapies are arriving, including complement C5 inhibitors, neonatal Fc receptor inhibitors, B-cell inhibitors, plasma cell inhibitors, and various cytokines and chemokines. Prof. Claeys mainly focussed on complement C5 inhibitors and neonatal Fc receptor inhibitors [1].
The neonatal Fc receptor inhibitor efgartigimod was tested among 167 patients with generalised MG in the phase 3 ADAPT trial [2]. The included participants were randomised 1:1 to receive efgartigimod as add-on therapy or to a placebo, for 26 weeks. A significantly larger proportion of participants on efgartigimod achieved an MG-ADL response (44/65 vs 19/64; P<0.0001). Efgartigimod had a favourable safety profile and displayed superior efficacy to placebo on other endpoints as well; results that led to the EMA approval of this agent for patients with generalised MG. “Next to efgartigimod, rozanolixizumab is an approved neonatal Fc receptor inhibitor for the MG population, and nipocalimab and batoclimab are still under investigation,” added Prof. Claeys.
Regarding complement C5 inhibitors, the phase 3 REGAIN trial compared eculizumab with a placebo in 125 patients with generalised MG [3]. The randomisation occurred in a 1:1 fashion and lasted for 26 weeks. “Although the primary endpoint of ‘MG-ADL change from baseline at week 26’ was not met, the results were good, and EMA approval was provided,” said Prof. Claeys. “Also, few adverse events were seen with this agent.” Ravulizumab and zilucoplan are other EMA-approved complement C5 inhibitors for the treatment of patients with generalised MG and pozelimab, cemdisiran, and gefurulimab are all being tested in phase 3 trials.
“The new biological therapies work faster, more selective, target-specific, and come with an acceptable safety profile,” summarised Prof. Claeys. “Nonetheless, there are many issues to be resolved, such as deciding which position these therapies take in the treatment cascade, collecting evidence on long-term efficacy and safety, and determining the value of these therapies during myasthenic crises.”
- Claeys K, et al. Advances of treatments in myasthenia gravis. 10th EAN Congress, 29 June–2 July 2024, Helsinki, Finland.
- Howard JF, et al. Lancet Neurol. 2021;20:526-536.
- Howard JF, et al. Lancet Neurol. 2017;16(12):976-986.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« High risk for recurrent vascular events in young stroke patients Next Article
How to achieve goal-concordant care in severe acute brain injury? »
« High risk for recurrent vascular events in young stroke patients Next Article
How to achieve goal-concordant care in severe acute brain injury? »
Table of Contents: EAN 2024
Featured articles
Extended success for N-acetyl-L-leucine in Niemann-Pick disease type C
Treatment escalation and de-escalation in late-onset MS
Diagnostics and Disease Management in Neurology
What is the value of transcranial ultrasound for diagnosing Parkinson’s disease?
How to achieve goal-concordant care in severe acute brain injury?
Changing treatment landscape in myasthenia gravis
Stroke and Vascular Events
High risk for recurrent vascular events in young stroke patients
Anticoagulation or antiplatelet as secondary prevention for cancer-related strokes?
Multiple Sclerosis
Treatment escalation and de-escalation in late-onset MS
How different are late onset and adult onset MS really?
Advances in Neurostimulation
Vagal nerve stimulation for the reduction of cognitive impairment in Alzheimer’s disease
Spinal cord stimulation for chronic pain: state-of-affairs in 2024
Innovations in VNS and DBS for refractory epilepsy
Genetic and Molecular Therapies
Extended success for N-acetyl-L-leucine in Niemann-Pick disease type C
Therapeutic advancement in spinal muscular atrophy
Therapeutic advancement in Pompe disease
Neurological Risk Factors and Predictive Tools
Under investigation: Opioid use and the risk for dementia
Novel tool to predict outcomes in anti-NMDAR encephalitis
Related Articles
November 25, 2020
Anti-CD20 DMTs associated with worse COVID-19 outcomes
October 15, 2021
Auditory training may improve thinking in early schizophrenia
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com